AIM: To evaluate the effects of panretinal photocoagulation(PRP) compared with PRP plus intravitreal bevacizumab(IVB) in patients with high-risk proliferative diabetic retinopathy(PDR) according to the Early Treatment...AIM: To evaluate the effects of panretinal photocoagulation(PRP) compared with PRP plus intravitreal bevacizumab(IVB) in patients with high-risk proliferative diabetic retinopathy(PDR) according to the Early Treatment Diabetic Retinopathy Study criteria.· METHODS: The data were collected retrospectively from the eyes of high-risk PDR patients, which were divided into two groups. After treated with standard PRP,the eyes were randomly assigned to receive only PRP(PRP group) or PRP plus intravitreal injection of 1.25 mg of bevacizumab(PRP-Plus group). Patients underwent complete ophthalmic evaluation, including best corrected visual acuity(BCVA), intraocular pressure(IOP), and new vessel size in fluorescein angiography(FA) and optical coherence tomography for the assessment of central subfield macular thickness(CSMT) at baseline and at weeks 12(±2), 16(±2), 24(±2) and 48(±2). Main outcome measures also included vitreous clear-up time and neovascularization on the disc(NVD) regression time.Adverse events associated with intravitreal injection were investigated.·RESULTS: Thirty consecutive patients(n =36 eyes)completed the 48-week follow-up. There was no significant difference between the PRP and PRP-Plus groups with respect to age, gender, type or duration of diabetes, area of fluorescein leakage from active neovascularizations(NVs), BCVA or CSMT at baseline.The mean vitreous clear-up time was 12.1 ±3.4wk after PRP and 8.4 ±3.5wk after PRP combined with IVB. The mean time interval from treatment to complete NVD regression on FA examination was 15.2 ±3.5wk in PRP group and 12.5±3.1wk in PRP-Plus group. No significant difference in CSMT was observed between the groups throughout the study period. However, the total area of actively leaking NVs was significantly reduced in the PRP-Plus group compared with the PRP group(P <0.05).Patients received an average of 1.3 injections(range:1-2).Ten eyes(27.8%) underwent 2 injections. Two eyes had ocular complication of PDR progression to dense vitreous hemorrhage(VH). No major adverse events were identified.·CONCLUSION: The adjunctive use of IVB with PRP is associated with a greater reduction in the area of active leaking NVs than PRP alone in patients with high-risk PDR. Short-term results suggest combined IVB and PRP achieved rapid clearance of VH and regression of retinal NV in the treatment of high-risk PDR. Further studies are needed to determine the effect of repeated intravitreal bevacizumab injections and the proper number of bevacizumab injections as an adjuvant.展开更多
AIM: Age-related macular degeneration (AMD) is the leading cause of blindness in the developed world and complement factor H (CFH) polymorphism has been found to associate with the AMD. To investigate whether the Y402...AIM: Age-related macular degeneration (AMD) is the leading cause of blindness in the developed world and complement factor H (CFH) polymorphism has been found to associate with the AMD. To investigate whether the Y402H variant in CFH is associated with AMD in Chinese populations, a systematic review and meta-analysis were performed to estimate the magnitude of the gene effect and the possible mode of action. · METHODS: A meta-analysis was performed using data available from ten case-control studies assessing association between the CFH Y402H polymorphism and AMD in Chinese populations involving 1538 AMD. Data extraction and study quality assessment were performed in duplicate. Summary odds ratios (ORs) and 95% confidence intervals (CIs) an allele contrast and genotype contrast were estimated usingfixed- effects models. The Q-statistic test was used to assess heterogeneity, and Funnel plot was used to evaluate publication bias. · RESULTS: Seven of ten case-control studies were neovascular AMD, and few studies came from west and north of China. There was strong evidence for association between CFH and AMD in Chinese population, with those having risk allele C 2.35 times more likely to have AMD than subjects with T allele. Evidence of publication bias was not observed in our meta-analysis. · CONCLUSION: This meta-analysis summarizes the strong evidence for an association between CFH and AMD in Chinese and indicates each C allele increasing the odds of AMD by 2.33-fold.But more evidences about the relation between CFH polymorphism and different type of Chinese AMD from various district were needed.展开更多
文摘AIM: To evaluate the effects of panretinal photocoagulation(PRP) compared with PRP plus intravitreal bevacizumab(IVB) in patients with high-risk proliferative diabetic retinopathy(PDR) according to the Early Treatment Diabetic Retinopathy Study criteria.· METHODS: The data were collected retrospectively from the eyes of high-risk PDR patients, which were divided into two groups. After treated with standard PRP,the eyes were randomly assigned to receive only PRP(PRP group) or PRP plus intravitreal injection of 1.25 mg of bevacizumab(PRP-Plus group). Patients underwent complete ophthalmic evaluation, including best corrected visual acuity(BCVA), intraocular pressure(IOP), and new vessel size in fluorescein angiography(FA) and optical coherence tomography for the assessment of central subfield macular thickness(CSMT) at baseline and at weeks 12(±2), 16(±2), 24(±2) and 48(±2). Main outcome measures also included vitreous clear-up time and neovascularization on the disc(NVD) regression time.Adverse events associated with intravitreal injection were investigated.·RESULTS: Thirty consecutive patients(n =36 eyes)completed the 48-week follow-up. There was no significant difference between the PRP and PRP-Plus groups with respect to age, gender, type or duration of diabetes, area of fluorescein leakage from active neovascularizations(NVs), BCVA or CSMT at baseline.The mean vitreous clear-up time was 12.1 ±3.4wk after PRP and 8.4 ±3.5wk after PRP combined with IVB. The mean time interval from treatment to complete NVD regression on FA examination was 15.2 ±3.5wk in PRP group and 12.5±3.1wk in PRP-Plus group. No significant difference in CSMT was observed between the groups throughout the study period. However, the total area of actively leaking NVs was significantly reduced in the PRP-Plus group compared with the PRP group(P <0.05).Patients received an average of 1.3 injections(range:1-2).Ten eyes(27.8%) underwent 2 injections. Two eyes had ocular complication of PDR progression to dense vitreous hemorrhage(VH). No major adverse events were identified.·CONCLUSION: The adjunctive use of IVB with PRP is associated with a greater reduction in the area of active leaking NVs than PRP alone in patients with high-risk PDR. Short-term results suggest combined IVB and PRP achieved rapid clearance of VH and regression of retinal NV in the treatment of high-risk PDR. Further studies are needed to determine the effect of repeated intravitreal bevacizumab injections and the proper number of bevacizumab injections as an adjuvant.
文摘AIM: Age-related macular degeneration (AMD) is the leading cause of blindness in the developed world and complement factor H (CFH) polymorphism has been found to associate with the AMD. To investigate whether the Y402H variant in CFH is associated with AMD in Chinese populations, a systematic review and meta-analysis were performed to estimate the magnitude of the gene effect and the possible mode of action. · METHODS: A meta-analysis was performed using data available from ten case-control studies assessing association between the CFH Y402H polymorphism and AMD in Chinese populations involving 1538 AMD. Data extraction and study quality assessment were performed in duplicate. Summary odds ratios (ORs) and 95% confidence intervals (CIs) an allele contrast and genotype contrast were estimated usingfixed- effects models. The Q-statistic test was used to assess heterogeneity, and Funnel plot was used to evaluate publication bias. · RESULTS: Seven of ten case-control studies were neovascular AMD, and few studies came from west and north of China. There was strong evidence for association between CFH and AMD in Chinese population, with those having risk allele C 2.35 times more likely to have AMD than subjects with T allele. Evidence of publication bias was not observed in our meta-analysis. · CONCLUSION: This meta-analysis summarizes the strong evidence for an association between CFH and AMD in Chinese and indicates each C allele increasing the odds of AMD by 2.33-fold.But more evidences about the relation between CFH polymorphism and different type of Chinese AMD from various district were needed.
